Cargando…
Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial
The cell and gene therapy product AGT103-T was designed to restore the Gag-specific CD4+ T cell response in persons with chronic HIV disease who are receiving antiretroviral therapy. This autologous, genetically engineered cell product is under investigation in a Phase 1 clinical trial (NCT03215004)...
Autores principales: | Muvarak, Nidal, Li, Haishan, Lahusen, Tyler, Galvin, Jeffrey A., Kumar, Princy N., Pauza, C. David, Bordon, José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701732/ https://www.ncbi.nlm.nih.gov/pubmed/36452901 http://dx.doi.org/10.3389/fmed.2022.1044713 |
Ejemplares similares
-
Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, LentivirusModified CD4 T Cells for HIV Functional Cure
por: Li, Haishan, et al.
Publicado: (2020) -
Reducing farnesyl diphosphate synthase levels activates Vγ9Vδ2 T cells and improves tumor suppression in murine xenograft cancer models
por: Liou, Mei-Ling, et al.
Publicado: (2022) -
Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local
por: Pauza, C. David, et al.
Publicado: (2018) -
Association Between AGT M235T and Left Ventricular Mass in Vietnamese Patients Diagnosed With Essential Hypertension
por: Tran, Tuan Thanh, et al.
Publicado: (2021) -
Critical roles for Akt kinase in controlling HIV envelope-mediated depletion of CD4 T cells
por: Li, Haishan, et al.
Publicado: (2013)